Condition
Radioligand
Total Trials
2
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Prostest
Related Conditions
Often studied with 14 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Early Phase 1 (1)
Trial Status
Recruiting1
Enrolling By Invitation1
Clinical Trials (2)
Research Network
Common Treatments
- Prostest1
- Radioligand 11cchdi004910091
Active Sponsors
- Wren Laboratories LLC1
- CHDI Foundation, Inc.1
- University Hospital Muenster1
- Universitaire Ziekenhuizen KU Leuven1
Top Investigators
Munster University Hospital
Wren Laboratories
Related Conditions
- Chemotherapy1
- Prostate Biopsy1
- Androgen Deprivation Therapy1
- Hd1
- Imaging1